LTR Pharma Secures Exclusive U.S. Pharmacy Partner for ROXUS
Key points
- Binding term sheet with Strive Specialties Inc. established for ROXUS
- Provides access to healthcare provider and clinic networks
- Multi-state 503A pharmacy platform supports national pharmacy infrastructure
- Key milestone in US commercialization strategy for ROXUS
Full summary
LTR Pharma Limited (ASX:LTP) has executed a binding term sheet with Strive Specialties Inc., a US personalized medicine and 503A pharmacy, establishing exclusive US pharmacy fulfillment rights for ROXUS®. This agreement provides LTR Pharma with the necessary infrastructure to supply ROXUS in the United States, enhancing its commercialization strategy for the erectile dysfunction market. The arrangement includes Strive Pharmacy's multi-state 503A pharmacy platform, offering national pharmacy fulfillment infrastructure. The agreement is subject to the negotiation and execution of definitive agreements within 60 days, extending to 90 days by mutual agreement. If not completed, the term sheet will terminate, except for binding provisions, and exclusivity will end. The partnership aims to support the commercial launch of ROXUS through telehealth, pharmacy fulfillment, and healthcare provider networks.
Summary generated by a large language model. Please interpret with care.